Interim FDG-PET/CT does not predict outcome in newly diagnosed patients with mantle cell lymphoma treated with chemotherapy alone or chemo + ASCT

[1]Elena Ribakovsky, [1]Meirav Kedmi, [2]Irit Avivi, [2]Noam Benyamini, [3]Tima Davidson, [3]Elinor Goshen, [4]Rachel Bar Shalom, [5]Tamar Tadmor, [1]Arnon Nagler and [1]Abraham Avigdor.

[1]Department of Hematology and Bone Marrow Transplantation,[3]Department of Nuclear Medicine, Chaim Sheba Medical Center, Tel-Hashomer; [2]Department of Hematology and Bone Marrow transplantation, [4]PET scan Unit, Rambam Medical Center, Haifa; [5]Hematology Unit, Bnei-Zion Medical Center, Haifa; Israel.

Patient characteristics and treatment

Patients (n)	58
Gender F/M (n)	9/49
Age (median)	59 yrs (41-88)
Median follow-up	3.3 yrs (0.67-13.1)
Treatment (n) (%)	
R-CHOP	37 (64%)
R-CHOP/R-DHAP	5 (9%)
R-HyperCVAD	10 (17%)
Other	6 (10%)
ASCT	24 (41%)

Patient characteristics: chemo vs. chemo + ASCT

	Chemotherapy 34 (59%)	Chemotherapy+ASCT 24 (41%)	p
Gender (n=58)			
Male	29 (85%)	20 (83%)	NS
Female	5 (15%)	4 (17%)	
Age (n=58)			
<60	12 (35%)	19 (79%)	0.001
>=60	22 (65%)	5 (21%)	
Stage (n=58)			
I/II	3 (9%)	0 (0%)	NS
III/IV	31 (91%)	24 (100%)	
GI involvement (n=58)			
No	28 (82%)	13 (54%)	0.04
Yes	6 (18%)	11 (46%)	
Interim PET (n=51)			
Neg	11 (35%)	9 (45%)	NS
Pos	20 (65%)	11 (55%)	
MIPI (n=49)			
Low	8 (27%)	14 (74%)	NS
Int	17 (57%)	3 (16%)	
High	5 (16%)	2 (10%)	
Ki67% (n=35%)			
<30%	12 (50%)	3 (27%)	NS
>=30%	12 (50%)	8 (73%)	

Survival outcomes

OS - entire cohort

A.

84% at 3 yrs

PFS - entire cohort

B.

48% at 3 yrs

OS entire cohort - MIPI

C.

p=0.02

low

int.

high

p=0.02

OS - ASCT subgroup

D.

82% at 3 yrs

Mid-term PET results do not predict outcome in the entire cohort

- 51/58 patients were scanned
- Pos. or neg. scores – based on revised response criteria (2007)
- Mid-term PET: neg.- 20, pos.- 31 [no difference in gender, MIPI, stage and B symptoms. Older age (≥60 yrs) more prevalent in PET pos. group (p=0.02)]

OS

p=NS

positive

negative

neg. 85% *vs.* pos. 90% at 3 yrs.

PFS

p=NS

negative

positive

neg. 57% *vs.* pos. 44% at 3 yrs.

Neither mid-term nor pre-transplant PET results predict outcome in MCL patients treated with chemo and upfront ASCT

OS - mid-term PET

neg. 75% *vs.* pos. 90% at 3 yrs.

OS – pre-transplant PET

PFS at 3 yrs:
neg. 80% *vs.* pos. 66% (p=NS)

Conclusions

- Mid-term PET/CT results do not predict OS and PFS in newly diagnosed patients with MCL treated with chemotherapy.

- Neither interim nor pre-transplant PET results predict outcome in patients who receive consolidation with upfront autologous stem cell transplantation.

- Negative mid-term PET is more often achieved in younger than in older patients with MCL.